Blue Whale Capital LLP Sells 2,000 Shares of DexCom, Inc. (NASDAQ:DXCM)

Blue Whale Capital LLP decreased its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 1.6% during the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 123,000 shares of the medical device company’s stock after selling 2,000 shares during the quarter. DexCom makes up 1.2% of Blue Whale Capital LLP’s holdings, making the stock its 18th largest holding. Blue Whale Capital LLP’s holdings in DexCom were worth $13,946,000 at the end of the most recent quarter.

Other institutional investors have also bought and sold shares of the company. Migdal Insurance & Financial Holdings Ltd. purchased a new position in shares of DexCom in the second quarter valued at about $25,000. Sachetta LLC lifted its holdings in shares of DexCom by 255.2% in the second quarter. Sachetta LLC now owns 238 shares of the medical device company’s stock worth $27,000 after buying an additional 171 shares in the last quarter. DSM Capital Partners LLC bought a new position in shares of DexCom during the fourth quarter worth $28,000. Crewe Advisors LLC purchased a new position in DexCom during the first quarter valued at $29,000. Finally, Riverview Trust Co purchased a new stake in DexCom in the 1st quarter worth $32,000. Hedge funds and other institutional investors own 97.75% of the company’s stock.

DexCom Trading Down 2.1 %

DXCM opened at $70.43 on Friday. The company has a current ratio of 2.82, a quick ratio of 2.48 and a debt-to-equity ratio of 1.00. The firm has a market cap of $28.01 billion, a price-to-earnings ratio of 45.44, a PEG ratio of 2.12 and a beta of 1.18. DexCom, Inc. has a 12 month low of $62.34 and a 12 month high of $142.00. The stock has a fifty day moving average price of $78.19 and a 200-day moving average price of $109.63.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Thursday, July 25th. The medical device company reported $0.43 earnings per share for the quarter, topping the consensus estimate of $0.39 by $0.04. DexCom had a return on equity of 31.41% and a net margin of 16.95%. The business had revenue of $1 billion during the quarter, compared to the consensus estimate of $1.04 billion. During the same quarter last year, the company earned $0.34 earnings per share. The company’s quarterly revenue was up 15.3% on a year-over-year basis. As a group, equities research analysts anticipate that DexCom, Inc. will post 1.69 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other DexCom news, COO Jacob Steven Leach sold 746 shares of the firm’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $51,585.90. Following the completion of the transaction, the chief operating officer now owns 264,915 shares of the company’s stock, valued at $18,318,872.25. The transaction was disclosed in a filing with the SEC, which is available at this link. In other news, COO Jacob Steven Leach sold 746 shares of the firm’s stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $51,585.90. Following the completion of the transaction, the chief operating officer now directly owns 264,915 shares in the company, valued at $18,318,872.25. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Michael Jon Brown sold 652 shares of the company’s stock in a transaction that occurred on Wednesday, July 31st. The shares were sold at an average price of $69.55, for a total value of $45,346.60. Following the completion of the sale, the executive vice president now owns 66,249 shares in the company, valued at approximately $4,607,617.95. The disclosure for this sale can be found here. In the last quarter, insiders have sold 2,483 shares of company stock valued at $201,708. Insiders own 0.30% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on DXCM shares. Canaccord Genuity Group reiterated a “buy” rating and issued a $145.00 target price on shares of DexCom in a research report on Tuesday, July 23rd. Baird R W lowered shares of DexCom from a “strong-buy” rating to a “hold” rating in a report on Friday, July 26th. Oppenheimer decreased their price target on shares of DexCom from $150.00 to $115.00 and set an “outperform” rating on the stock in a research note on Friday, July 26th. UBS Group lowered their price objective on shares of DexCom from $163.00 to $95.00 and set a “buy” rating for the company in a research report on Friday, July 26th. Finally, Stifel Nicolaus boosted their target price on shares of DexCom from $90.00 to $100.00 and gave the stock a “buy” rating in a report on Friday, August 23rd. Seven equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $112.25.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.